Skip to main content

Navigating the Frontier of Hematologic Malignancy Therapies

This activity will cover the latest advances in the therapeutic management of hematologic malignancies, including bispecific antibodies, CAR-T products, proteolysis-targeting chimeras, and antibody-drug conjugates — with an emphasis on novel targets and approaches. The prognostic role of circulating tumor DNA is also explored.

Jointly provided by The Leukemia & Lymphoma Society and RMEI Medical Education, LLC.

The educational portion of this program is supported by an independent educational grant from AstraZeneca Pharmaceuticals LP. Additional funding provided by The Leukemia & Lymphoma Society

Series Courses